PTC Therapeutics, Inc.
PTCT
株式のランク
#3481
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
株価
$59.28
最終同期: 2026-10-16
時価総額
$4.95B
変化（1日）
-2.80%
変化（1年）
-10.11%
国
US
取引 PTC Therapeutics, Inc. (PTCT)
カテゴリー
Healthcare
PTC Therapeutics, Inc.（PTCT）の営業利益率
October 2026 時点の営業利益率 TTM: 11.52%
PTC Therapeutics, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 11.52% です。2023 年末時点では -37.26% でした。
PTC Therapeutics, Inc. の営業利益率の履歴（2011 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 11.52% | -130.72% |
| 2024 | -37.50% | 0.64% |
| 2023 | -37.26% | -40.81% |
| 2022 | -62.95% | -9.58% |
| 2021 | -69.62% | -38.60% |
| 2020 | -113.39% | 80.56% |
| 2019 | -62.80% | 43.71% |
| 2018 | -43.70% | 32.14% |
| 2017 | -33.07% | -79.29% |
| 2016 | -159.67% | -64.88% |
| 2015 | -454.58% | 5.00% |
| 2014 | -432.93% | 198.74% |
| 2013 | -144.92% | 55.58% |
| 2012 | -93.15% | -401.46% |
| 2011 | 30.90% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -96.65% |
US
|
|
| -149.01% | -112.93% |
US
|
|
| 25.57% | -97.78% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.50% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。